

May 15, 2021

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 023 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor Plot No.C/1, 'G'Block, Bandra- Kurla Complex Bandra East Mumbai 400 051 Fax No.2659 8237/8238 Stock Code: ROSSARI
---	--

Dear Sir/Madam,

Subject: Q4 & FY21 Press Release

Please find enclosed a copy of the Press Release for the quarter and financial year ended March 31, 2021.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,
For Rossari Biotech Limited



Parul Gupta
Company Secretary & Compliance Officer
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED
(An ISO 9001:2015 & 14001:2015 Certified Company)

Regd. Office : 201 A & B, Ackruti Corporate Park, Next to GE Gardens, LBS Marg, Kanjurmarg (W). Mumbai - 400078. India. T +91-22-6123 3800 F +91-22-2579 6982
Factory : Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/11/1, Kumbharwadi, Village Naroli, Dadra & Nagar Haveli (U.T.), Silvassa - 396 235. India. T 0260 - 669 3000
E info@rossarimail.com W www.rossari.com CIN: L24100MH2009PLC194818



Rossari Biotech Limited

Corporate Office: 201 A & B Ackruti Corporate Park LBS Marg Next to G. E. Gardens,
Kanjurmarg West, Mumbai, Maharashtra 400078

Rossari Biotech announces Q4 & FY21 results

<u>Q4 FY21</u>	<u>FY21</u>
Revenues at Rs. 218.2 Cr, higher by 36.8% YoY	Revenues at Rs. 709.3 Cr, higher by 18.2% YoY
EBITDA improves by 46.7% YoY to Rs. 35.2 Cr	EBITDA improves by 17.4% YoY to Rs. 123.0 Cr
PAT at Rs. 22.2 Cr, higher by 47.1% YoY	PAT at Rs. 80.0 Cr, higher by 22.7% YoY

Mumbai, May 14, 2021: Rossari Biotech Limited (Rossari), a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the fourth quarter and year ended March 31, 2021.

Q4 FY21 performance overview compared with Q4 FY20

- Revenues from operations stood at Rs. 218.2 crore as against Rs. 159.5 crore, higher by 36.8%
- EBITDA at Rs. 35.2 crore as against Rs. 24.0 crore, up by 46.7%
- PAT stood at Rs. 22.2 crore as against Rs. 15.1 crore, higher by 47.1%
- EPS (Diluted) stood at Rs. 4.29 as against Rs. 3.06

FY21 performance overview compared with FY20

- Revenues from operations stood at Rs. 709.3 crore as against Rs. 600.1 crore, higher by 18.2%
- EBITDA at Rs. 123.0 crore as against Rs. 104.8 crore, up by 17.4%
- PAT stood at Rs. 80.0 crore as against Rs. 65.2 crore, higher by 22.7%
- EPS (Diluted) stood at Rs. 15.47 as against Rs. 13.23

Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said:

“We are pleased to share that we have reported a strong operational and financial performance during the quarter, with revenues higher by 36.8% YoY and PAT up by 47.1% YoY. Growth was primarily driven by a robust and continued uptick in sales in the HPPC segment led by higher offtake in hygiene products and anti-viral portfolio sales. In addition, normalization in demand and improved consumption across the TSC and AHN business lines assisted overall results. Even on a full year basis, our performance, despite the unprecedented environment, has been resilient and we have ended FY2021 on a strong note, with revenues higher by 18.2% YoY and PAT higher by 22.7% YoY.

In one of the key developments during the quarter, we have fully operationalized our state-of-the-art Greenfield manufacturing facility at Dahej. We have seen a strong ramp-up in utilization levels from this facility in recent months, leading to healthy volumes particularly in the HPPC segment. Going forward, a strong upcoming pipeline of new product launches should enable us to sustainably ramp-up utilization levels at this unit over the next 3-4 years.

In the quarter gone by, we had seen normalization in demand and consumption sentiments across all the three business segments. While the environment has evolved with the second wave of COVID-19 infections, we believe, wider vaccination coverage and limited lockdowns should restore normalcy sooner than later. Overall, we are confident that the stabilization of the demand environment and improved consumption will lead to stronger and sustainable growth in the quarters ahead.

We believe, healthy corporate governance practices are one of the pillars for long-term value creation. In-sync with this approach, in March 2021, the Board approved the Company’s dividend distribution policy. During FY21, we have announced a dividend of Rs. 0.50 per share.”

Key Developments:

All phases of Rossari’s Greenfield manufacturing facility at Dahej, Gujarat fully operationalised

- During the quarter, the Company successfully commissioned all phases of its Greenfield manufacturing facility at Dahej, Gujarat
- The facility is a state-of-the-art automated unit and enjoys proximity to various ports bringing solid cost and logistical advantages to the Company

- The unit has a total installed capacity 132,500 MTPA, enhancing the total capacity of Rossari by 2.1x to 252,500 MTPA. The Company expects to sustainably ramp-up utilization levels at the Dahej unit over the next 3-4 years
- The facility will be further augmented by R&D, automation, administration, and other corporate facilities in the coming quarters

Issued Equity Shares aggregating to ₹ 300 crore on Preferential Basis

- Rossari's Board of Directors approved the allotment of 30,12,046 equity shares of face value of ₹ 2/- each, on a preferential basis with a floor price of ₹ 996 per Equity Share, aggregating to ₹ 300 crore. The issue has brought on board high-quality and marquee shareholders of scale and repute
- The funds from this issue has further strengthened the Company's balance sheet profile and augmented the financial flexibility to address medium-to-long term growth prospects
- Rossari proposes to utilize the net proceeds to evaluate & invest in inorganic growth opportunities, within its core chemistries

Announces annual dividend of Rs. 0.50 per share

- For FY 2020-21, the Board of Directors recommended a dividend of Rs. 0.50 /- per share
- For details on dividend distribution policy, please refer to the Company's website at [Rossari - Dividend Distribution Policy](#)

About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates 2 strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For more information, please visit www.rossari.com OR contact:

Manasi Nisal

Rossari Biotech Limited

Tel: +91 22 6123 3800

Email: manasi.nisal@rossarimail.com

Anoop Poojari / Shikha Kshirsagar

CDR India

Tel: +91 98330 90434

Email: anoop@cdr-india.com

shikha@cdr-india.com

DISCLAIMER:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.